[go: up one dir, main page]

NO863980D0 - Fremgangsmaate for fremstilling av kinazolinderivater. - Google Patents

Fremgangsmaate for fremstilling av kinazolinderivater.

Info

Publication number
NO863980D0
NO863980D0 NO863980A NO863980A NO863980D0 NO 863980 D0 NO863980 D0 NO 863980D0 NO 863980 A NO863980 A NO 863980A NO 863980 A NO863980 A NO 863980A NO 863980 D0 NO863980 D0 NO 863980D0
Authority
NO
Norway
Prior art keywords
preparation
alkyl
procedure
pharmaceutically acceptable
carboxy
Prior art date
Application number
NO863980A
Other languages
English (en)
Other versions
NO171785C (no
NO171785B (no
NO863980L (no
Inventor
Masashi Hashimoto
Teruo Oku
Yoshikuni Ito
Takayuki Namiki
Kozo Sawada
Chiyoshi Kasahara
Yukihisa Baba
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO863980D0 publication Critical patent/NO863980D0/no
Publication of NO863980L publication Critical patent/NO863980L/no
Publication of NO171785B publication Critical patent/NO171785B/no
Publication of NO171785C publication Critical patent/NO171785C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • C07D285/181,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/201,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/221,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/241,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO863980A 1985-10-07 1986-10-06 Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater NO171785C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858524663A GB8524663D0 (en) 1985-10-07 1985-10-07 Quinazoline derivatives

Publications (4)

Publication Number Publication Date
NO863980D0 true NO863980D0 (no) 1986-10-06
NO863980L NO863980L (no) 1987-04-08
NO171785B NO171785B (no) 1993-01-25
NO171785C NO171785C (no) 1993-05-05

Family

ID=10586291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO863980A NO171785C (no) 1985-10-07 1986-10-06 Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater

Country Status (23)

Country Link
US (2) US4734419A (no)
EP (1) EP0218999B1 (no)
JP (3) JPS6296476A (no)
KR (1) KR940007270B1 (no)
CN (1) CN1017242B (no)
AT (1) ATE60761T1 (no)
AU (1) AU596611B2 (no)
CA (1) CA1289139C (no)
DE (1) DE3677452D1 (no)
DK (1) DK158838C (no)
ES (1) ES2021266B3 (no)
FI (1) FI90234C (no)
GB (1) GB8524663D0 (no)
GR (1) GR3001502T3 (no)
HK (1) HK6993A (no)
HU (1) HU196972B (no)
IE (1) IE59309B1 (no)
IL (1) IL80213A (no)
NO (1) NO171785C (no)
SG (1) SG112092G (no)
SU (1) SU1588283A3 (no)
UA (1) UA5562A1 (no)
ZA (1) ZA867043B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
WO1988001270A1 (en) * 1986-08-21 1988-02-25 Pfizer Inc. Pyridopyrimidinediones
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
US4931440A (en) * 1987-07-29 1990-06-05 Fujisawa Pharmaceutical Company, Ltd. Uricosuric composition
WO1989002432A1 (fr) * 1987-09-16 1989-03-23 Taiho Pharmaceutical Company, Limited Derives de thienopyrimidine
JP2621460B2 (ja) * 1988-02-29 1997-06-18 藤沢薬品工業株式会社 利尿または降圧剤
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
DE59606237D1 (de) * 1995-08-31 2001-01-25 Clariant Gmbh Monoester der carboxymethylenanthranilsäuren und verfahren zu ihrer herstellung
DE19532052C2 (de) * 1995-08-31 1998-11-19 Clariant Gmbh Verfahren zur Herstellung von Chinazolinderivaten
DE69614986T2 (de) * 1995-12-26 2002-04-25 Sumitomo Chemical Co., Ltd. Verfahren zur Herstellung von Isatosäureanhydriden
WO1997024335A1 (en) * 1995-12-28 1997-07-10 Fuji Chemical Industry Co., Ltd. Process for the preparation of 3-dihalobenzyl-2,4-quinazolinedione derivatives
US5780628A (en) * 1996-02-01 1998-07-14 Sumitomo Chemical Company, Limited Process for producing dioxoquinazolines
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
KR100510614B1 (ko) * 1997-04-15 2005-08-30 씨에스아이알 식욕 억제 활성을 갖는 화합물의 제조를 위한 중간체 및이의 제조 방법
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
EP1004307B1 (en) * 1998-01-30 2002-09-04 R-Tech Ueno, Ltd. Ophthalmic composition
WO2000043015A1 (fr) * 1999-01-25 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Gouttes ophtalmologiques
CA2328877A1 (en) 1999-02-18 2000-08-24 R-Tech Ueno, Ltd. Composition for treatment of external secretion disorders except hypolacrimation
CA2366597A1 (en) * 1999-03-09 2000-09-14 Fujisawa Pharmaceutical Co., Ltd. Process for producing quinazoline derivative or salt thereof
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
AU2002215160A1 (en) 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
JP4273406B2 (ja) * 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
JP2005529076A (ja) * 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU2003223786A1 (en) * 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
EP1507534A4 (en) * 2002-05-10 2006-11-08 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
US7041676B2 (en) * 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US7557115B2 (en) * 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−4−オン化合物、組成物、および方法
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
EP1692112A4 (en) * 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2394983B1 (en) * 2006-07-19 2014-09-24 E.I. Du Pont De Nemours And Company Process for making 3-substituted 2-amino-5-halobenzamides
EP2368560A1 (en) 2007-03-12 2011-09-28 Zadec ApS An anti-diabetic extract of rooibos
EP2139330B1 (en) 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Methods involving aldose reductase inhibitors
CA2695331A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN102219759B (zh) * 2010-04-16 2013-07-24 中国科学院上海药物研究所 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
US8785483B2 (en) 2010-12-23 2014-07-22 The Board Of Regents Of The University Of Texas System Methods for treating COPD
EP2994141A4 (en) 2013-05-10 2016-11-23 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
MX2015015422A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
US9988399B2 (en) 2013-05-10 2018-06-05 Gilead Apollo, Llc Bicyclic compounds as ACC inhibitors and uses thereof
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
CN111499616B (zh) * 2020-05-07 2022-07-22 盐城工学院 一种芳杂环取代的喹唑啉酮衍生物及其合成方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016166A (en) * 1973-12-14 1977-04-05 Hisamitsu Pharmaceutical Co., Inc. 1-Nitrophenylquinazoline-2,4(1H,3H)-diones
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
CA1161036A (en) * 1980-05-15 1984-01-24 Masayuki Ishikawa Quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
EP0040793B1 (en) * 1980-05-22 1985-08-28 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
DD232702A1 (de) * 1982-09-20 1986-02-05 Adw Ddr Verfahren zur herstellung von 1,2,3,4-tetrahydrochinazolin-2,4-dion-essigsaeuren, deren salzen und estern
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
JPS59186963A (ja) * 1983-04-08 1984-10-23 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives

Also Published As

Publication number Publication date
KR940007270B1 (en) 1994-08-12
GR3001502T3 (en) 1992-11-23
US4734419A (en) 1988-03-29
DK459086D0 (da) 1986-09-25
NO171785C (no) 1993-05-05
JPH01125322A (ja) 1989-05-17
FI863917L (fi) 1987-04-08
ES2021266B3 (es) 1991-11-01
ZA867043B (en) 1987-07-29
IE59309B1 (en) 1994-02-09
CA1289139C (en) 1991-09-17
FI863917A0 (fi) 1986-09-29
CN1017242B (zh) 1992-07-01
HU196972B (en) 1989-02-28
FI90234C (fi) 1994-01-10
DK158838C (da) 1991-01-14
AU6358986A (en) 1987-04-09
DE3677452D1 (de) 1991-03-14
UA5562A1 (uk) 1994-12-28
JPS6296476A (ja) 1987-05-02
JPH05366B2 (no) 1993-01-05
HK6993A (en) 1993-02-05
JPH0482148B2 (no) 1992-12-25
DK459086A (da) 1987-04-08
DK158838B (da) 1990-07-23
IL80213A0 (en) 1987-01-30
NO171785B (no) 1993-01-25
FI90234B (fi) 1993-09-30
ATE60761T1 (de) 1991-02-15
US4883800A (en) 1989-11-28
EP0218999A3 (en) 1988-01-13
IL80213A (en) 1991-06-30
SU1588283A3 (ru) 1990-08-23
AU596611B2 (en) 1990-05-10
CN86106984A (zh) 1987-05-20
NO863980L (no) 1987-04-08
JPH0794447B2 (ja) 1995-10-11
HUT41747A (en) 1987-05-28
EP0218999A2 (en) 1987-04-22
JPH01131164A (ja) 1989-05-24
IE862520L (en) 1987-04-07
GB8524663D0 (en) 1985-11-13
KR870003998A (ko) 1987-05-06
SG112092G (en) 1992-12-24
EP0218999B1 (en) 1991-02-06

Similar Documents

Publication Publication Date Title
NO863980L (no) Fremgangsmaate for fremstilling av kinazolinderivater.
MX9306831A (es) Nuevos compuestos heterociclicos.
NO903438D0 (no) Fremgangsmaate for fremstilling av tiazolderivater.
FI862757A0 (fi) Pyridonkarbonsyraderivat och foerfarande foer framstaellning av dessa.
DK519985D0 (da) Quinoloncarboxylsyrederivater, fremgangsmaade til fremstilling deraf og antibakterielt middel indeholdende saadanne derivater
NO882334L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
ATE126796T1 (de) Quinazolinderivate und ihre herstellung.
DK283984D0 (da) Benzodiazepinderivater og fremgangsmaade til fremstilling deraf
ATE143658T1 (de) Pyrrolidin-derivate
DK168284D0 (da) Troponderivater
DK210387D0 (da) Heterocykliske forbindelser og fremgangsmaade til deres fremstilling samt farmaceutiske midler indeholdende disse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003